Articles

The 430,000 square-foot finished production facility will house multiple product types within the rare disease sector, including hemophilia. 

Novo Nordisk Financially Commits $1.2 Billion Toward New Danish Production Plant

A panel examines the gross-to-net bubble across various product mixes, how pricing impacts market access, and more.  

Trade & Channel Strategies 2024: A GTN Bubble Balancing Act

Videos

Kevin O’Meara discusses how patient service teams influence adherence from Direct-to-Patient models. 

Trade & Channel Strategies 2024: The Role of Patient Service Teams in Driving Direct-to-Patient Adherence

Bill Trombetta, PhD, professor, healthcare strategy, marketing, St. Joseph's University, discusses the breakout session at Trade & Channel Strategies in Philadelphia.

Trade & Channel Strategies 2024: Industry Audit—Analyzing Top Biopharmaceuticals Performance Metrics

A session provides considerations for manufacturers during development, rollouts, and implementation, specifically as it pertains to the HSSP perspective.  

Trade & Channel Strategies 2024: Lessons Learned and Considerations with Humira

Kevin O’Meara discusses Patient-Cetric 3.0 breakout session and the challenges of drug manufactures implementing Direct-to-Patient models.

Trade & Channel Strategies 2024: Key Challenges of Implementing Direct-to-Patient Models 

A session investigates the drivers of these shortages and ways to mitigate them. 

Trade & Channel Strategies 2024: A Deep Dive into Drug Shortages

Breakout session explores how direct-to-patient models shorten the time to diagnosis and therapy to improve patient outcomes.

Trade & Channel Strategies 2024: Patient-Centric 3.0 — How Direct-to-Patient is the New Commercialization Model

A case study explores a way to potentially transform commercial organizations, while driving revenue growth.

Trade & Channel Strategies 2024: Navigating Pharma and Its Distribution Models

A panel uncovers how distribution channels are aligning commercialization efforts. 

News